Brokerages Set Petmed Express Inc (PETS) PT at $18.00

Petmed Express Inc (NASDAQ:PETS) has earned an average rating of “Sell” from the six brokerages that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation and two have assigned a hold recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

A number of research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Petmed Express from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. ValuEngine downgraded shares of Petmed Express from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Finally, Craig Hallum cut their price target on shares of Petmed Express from $25.00 to $18.00 and set a “sell” rating on the stock in a report on Wednesday, January 23rd.

Several institutional investors have recently added to or reduced their stakes in the company. Virginia Retirement Systems ET AL increased its holdings in shares of Petmed Express by 1.0% during the 1st quarter. Virginia Retirement Systems ET AL now owns 53,100 shares of the company’s stock worth $1,210,000 after purchasing an additional 500 shares during the period. Great West Life Assurance Co. Can boosted its position in shares of Petmed Express by 2.0% during the 4th quarter. Great West Life Assurance Co. Can now owns 26,411 shares of the company’s stock valued at $566,000 after acquiring an additional 508 shares in the last quarter. Texas Permanent School Fund boosted its position in shares of Petmed Express by 3.8% during the 1st quarter. Texas Permanent School Fund now owns 14,037 shares of the company’s stock valued at $320,000 after acquiring an additional 508 shares in the last quarter. Carillon Tower Advisers Inc. boosted its position in shares of Petmed Express by 0.8% during the 1st quarter. Carillon Tower Advisers Inc. now owns 78,764 shares of the company’s stock valued at $1,794,000 after acquiring an additional 600 shares in the last quarter. Finally, Personal Capital Advisors Corp boosted its position in shares of Petmed Express by 0.7% during the 4th quarter. Personal Capital Advisors Corp now owns 92,032 shares of the company’s stock valued at $2,141,000 after acquiring an additional 681 shares in the last quarter. Institutional investors and hedge funds own 95.04% of the company’s stock.

Shares of NASDAQ:PETS traded down $0.86 during trading on Friday, reaching $19.51. 370,600 shares of the company traded hands, compared to its average volume of 679,359. The firm has a market capitalization of $409.14 million, a P/E ratio of 10.40 and a beta of 0.47. Petmed Express has a 1-year low of $18.84 and a 1-year high of $46.83.

Petmed Express (NASDAQ:PETS) last issued its earnings results on Monday, May 6th. The company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.14). The company had revenue of $64.57 million for the quarter, compared to analyst estimates of $69.06 million. Petmed Express had a net margin of 13.32% and a return on equity of 28.96%. The company’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period last year, the business earned $0.50 EPS.

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 24th. Stockholders of record on Friday, May 17th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 5.54%.

Petmed Express Company Profile

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

See Also: Do back-end load funds outperform no-load funds?

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.